21-羟化酶缺陷症的临床与基因诊断研究
摘要
先天性肾上腺皮质增生症(congenital adrenal hyperplasia，CAH)是一组常染色体隐性遗传性疾病。21-羟化酶缺陷症(21-hydroxylase deficiency，21-OHD)是CAH中最常见的一种，约占所有CAH病例的90％以上。21-OHD通常分为三种临床类型，即失盐型、单纯男性化型和非经典型，其中失盐型和单纯男性化型又合称为经典型。据文献报道，经典型21-OHD的发病率为1／14，554活产，相应的杂合子发生率为1／61，基因频率为0.0082，其中失盐型与单纯男性化型的比例为3.3：1。而非经典型21-OHD的发病率比经典型高得多，并且有明显的种族差异，是人类最常见的常染色体隐性遗传性疾病之一。
迄今为止，国内尚未见到一定规模的21-OHD的临床或基础研究报道，关于中国人中21-OHD各临床类型的发病情况、该病的临床、生化和遗传学特点，以及药物干预所带来的益处和治疗中存在的问题等等许多方面的问题都有待于我们去进一步观察。本研究的目的在于，对21-OHD患者的发病、临床和治疗特点进行较全面的分析总结，并对引起21-OHD的基因缺失和八种常见点突变进行研究，初步了解中国人中21-OHD的基因突变情况，建立起临床可行的21-OHD的基因诊断方法，并将基因诊断的方法初步应用于临床诊断和产前诊断，以及对21-OHD基因型与临床表现型之间的关系、在临床上诊断为特发性多毛的妇女中是否有被漏诊的非经典型21-OHD等进行初步探讨。
本研究对我院1964年10月—1993年9月的所有21—OHD病例进行回顾性分析，并从1993年9月起对部分患者和新病人进行前瞻性观察至1997年11月，共分析病例148例。观察的指标包括，患者的性别，家族史，初诊年龄，初诊时的临床表现包括失
Congenital adrenal hyperplasia (CAH) refers to a group of steroidogenic disorders in which an enzyme defect results in impaired synthesis of cortisol. The defects are transmitted as autosomal recessive traits. 21-Hydroxylase deficiency (21-OHD) is the most frequent type of CAH, which accounts for over 90% of patients with CAH. 21-OHD is generally categorized into three forms, i.e. salt wasting (SW), simple virilizing (SV) and nonclassic (NC). Salt wasting and simple virilizing forms are also called classic 21-OHD. The worldwide incidence of classic 21-OHD uncovered by the newborn screening programs was estimated to be 1 in 14,554 live birth for homozygotes, with the corresponding heterozygote (carrier) to be 1 in 61 persons and gene frequency to be 0.0082. The nonclassic 21-OHD is one of the most common autosomal recessive disorders, with the frequency ethnic-specific.
By far in China, neither much research has been reported, nor much is known about the incidence, clinical or genetic features of 21-OHD. The objective of this study was to summarize the clinical features of 21-OHD cases managed in our hospital, investigate its genetic features, establish the clinically and prenatally practicable genetic diagnosis, explore the relationship between phenotype and genotype, and uncover if nonclassic 21-OHD patients were misdiagnosed as idiopathic hirsutism.
Cases from October 1964 to September 1993 were retrospectively studied. Some of them and new cases were prospectively studied from September 1993 to November 1997. Data included patients' sex,
迄今为止，国内尚未见到一定规模的21-OHD的临床或基础研究报道，关于中国人中21-OHD各临床类型的发病情况、该病的临床、生化和遗传学特点，以及药物干预所带来的益处和治疗中存在的问题等等许多方面的问题都有待于我们去进一步观察。本研究的目的在于，对21-OHD患者的发病、临床和治疗特点进行较全面的分析总结，并对引起21-OHD的基因缺失和八种常见点突变进行研究，初步了解中国人中21-OHD的基因突变情况，建立起临床可行的21-OHD的基因诊断方法，并将基因诊断的方法初步应用于临床诊断和产前诊断，以及对21-OHD基因型与临床表现型之间的关系、在临床上诊断为特发性多毛的妇女中是否有被漏诊的非经典型21-OHD等进行初步探讨。
本研究对我院1964年10月—1993年9月的所有21—OHD病例进行回顾性分析，并从1993年9月起对部分患者和新病人进行前瞻性观察至1997年11月，共分析病例148例。观察的指标包括，患者的性别，家族史，初诊年龄，初诊时的临床表现包括失
Congenital adrenal hyperplasia (CAH) refers to a group of steroidogenic disorders in which an enzyme defect results in impaired synthesis of cortisol. The defects are transmitted as autosomal recessive traits. 21-Hydroxylase deficiency (21-OHD) is the most frequent type of CAH, which accounts for over 90% of patients with CAH. 21-OHD is generally categorized into three forms, i.e. salt wasting (SW), simple virilizing (SV) and nonclassic (NC). Salt wasting and simple virilizing forms are also called classic 21-OHD. The worldwide incidence of classic 21-OHD uncovered by the newborn screening programs was estimated to be 1 in 14,554 live birth for homozygotes, with the corresponding heterozygote (carrier) to be 1 in 61 persons and gene frequency to be 0.0082. The nonclassic 21-OHD is one of the most common autosomal recessive disorders, with the frequency ethnic-specific.
By far in China, neither much research has been reported, nor much is known about the incidence, clinical or genetic features of 21-OHD. The objective of this study was to summarize the clinical features of 21-OHD cases managed in our hospital, investigate its genetic features, establish the clinically and prenatally practicable genetic diagnosis, explore the relationship between phenotype and genotype, and uncover if nonclassic 21-OHD patients were misdiagnosed as idiopathic hirsutism.
Cases from October 1964 to September 1993 were retrospectively studied. Some of them and new cases were prospectively studied from September 1993 to November 1997. Data included patients' sex,
引文
1. Sydnor KL, Kelley VC, Raile RB, et al: Blood adrenocorticotropin in children with congenital adrenal hyperplasia. Proc Soc Exp Biol Med. 1953; 82:695.
2. Binoux M, Pham-Huu-Trung MT, Gourmelen M, et al: Plasma ACTH in adrenogenital syndrome. Acta Paediatr Scand. 1972; 61:269.
3. Ganong WF, Alpert LC, Lee TC: ACTH and the regulation of adrenocortical secretion. N Engl J Med. 1974; 290:1006.
4. New MI, White PC, Pang S, Dupont B, Speiser PW: The adrenal hyperplasia. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th Ed. New York, McGraw-Hill. 1989, ppl881-1917.
5. Pang S, Wallace MA, Hofman L, et al: Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988; 81:866-874.
6. Pang S, Murphey W, Levine LS: A pilot newborn screening for congenital adrenal hyperplasia (CAH) in Alaska. Pediatr Res. 1981; 15:512.
7. New MI: Congenital adrenal hyperpalsia. In DeGroot LJ, Besser M, Burger HG, et al. (eds): Endocrinology, 3rd ed. Pennsylvania, W.S. Saunders Company. 1995, ppl813-1835.
8. Miller WL and Tyrrell JB: The adrenal Cortex, in Felig P, Baxter JD and Frohman LA (eds): Endocrinology and Metabolism, 3rd ed. New York, McGraw-Hill, Inc.. 1995, pp555-711.
9. Tusie-Luna M.-T., Speiser PW, Dumic M., et al: A mutation (Pro-30 to Leu-30) in CYP21 represents a potential nonclassic steroid 21- hydroxylase deficiency allele. Molec Endocr. 1991; 5:685.
10. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem. 1990; 265:20916-20922.
11. Wu DA, Chung BC: Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281 and Ser268 result in complete, partial or no loss of enzymatic activity, respectively. J Clin Invest. 1991; 88:519-523.
12. Marshall WA and Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44:291 -301.
13. Van Wieringen JC, Wafelbakker F, Verbugge HP, et al: Growth Diagrams 1965 Netherlands: Second national survey on 0-24 year olds. Netherlands Institute for Preventive Medicine TNO Leiden, Wolters-Noordhoff Publishing, Groningen, 1971.
14. Reynolds EL and Wines JV: Individual differences in physical changes associated with adolescence in girls. Am J Dis Child. 1948; 75:329.
15. Dupertuis CW, Atkinson WB and Elftman H: Sex differences in pubic hair distribution. Hum Biol. 1945; 17:137.
16. Marshall WA and. Timer JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970; 45:13-23.
17. Reynolds EL and Wines JV: Physical changes associated with adolescence in boys. Am J Dis Child. 1951; 82: 29.
18. Prader A: Die haufigkeit der kongenitalen adrenogenitalen syndromes. Helv Paediatr Acta. 1958; 13: 5.
19. Kaplan SL and Grumbach MM: Pathophysiology and treatment of sexual precocity. J Clin Ehdocrinol Metab. 1990; 71: 785.
20. Nicholson AB and Hanley C: Indices of physiological maturity: Derivation and interrelationships. Child Dev. 1953; 24: 3.
21. Zacharias L, Rand WM and Wurtman RJ: A prospective study of sexual development in American girls: The statistics of menarche. Obstet Gynecol Surv. 1976; 31: 325.
22. Styne DM and Grumbach MM: Puberty in the male and female: Its physiology and disorders. In Samuel S. C. Yen and Robert B. Jaffe(eds): Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 2nd Ed. Pennsylvania, W. S. Saunders Company. 1986, pp313-384.
23. Root AW and Reiter ED: Evaluation and management of the child with delayed pubertal development. Fertil Steril. 1976; 27: 745-755.
24．池芝盛等(编译)：内分泌学基础与临床．北京科学技术出版社．1992，pp491．
25. New MI, Gertner JM, Speiser PW, et al: Growth and final height in classic and nonclassic 21-hydroxylase deficiency. Acta Paediatr Jpn. 1988; 30(suppl): 79-88.
26. Miller WL: The adrenal Cortex. In Rudolph AM, Hoffman JIE, Rudolph CR(eds): Rudolph's Pediatrics, 19th Ed. Norwalk, Conn., Appleton & Lange. 1991, pp 1584.
27. Klingensmith JG, Garcia SC, Jones HW Jr, et al: Glucocorticoid treatment of girls with congenital adrenal hyperplasia: Effects on height, sexual matuation and fertility. J Pediatr. 1977; 90: 996.
28. Mulaikal R, Migeon CJ, Rock JA: Fertility rates in female patients with congenital hyperplasia due to 21-hydroxylase dficiency. N Engl J Med. 1987; 316: 178.
29. Migeon CJ and Donohoue PA: Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: Its molecular basis and its remaining therapeutic problems, in Nelson DH(ed): Endocrinology and Metabolism Clinics of North America: New Concept of Adrenal Disease. Endocrinol Metab Clin Nor Am. 1991; 20(2): 277-296.
30. Wilson RC, Mercado AB, Cheng KC, et al: Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab. 1995; 80: 2322-2329.
31．竹田亮佑，森本真本，宫森勇等：醛固酮是从肾上腺皮质球状带分泌的最强的盐皮质激素．综合临床．1978；27(suppl)：332-337．
1. New MI, White PC, Pang S, Dupont B, Speiser PW: The adrenal hyperplasia, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th Ed. New York, McGraw-Hill, 1989, pl881-1917.
2. Pang S, Wallace MA, Hofman L, et al: Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988; 81:866-874.
3. White PC, New MI, Dupont B: Structure of human steroid 21- hydroxylase gene. Proc Natl Acad Sci USA. 1986; 83:5111 -5115.
4. Higashi Y, Yoshioka H, Yamane M, et al: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudogene and a genuine gene. Proc NatlA cad Sci USA. 1986; 83:2841-2845.
5. Mercado AB, Wilson RC, et al: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol metab. 1995; 80: 2014-2020.
6. Speiser PW, Dupont J, Zhu D, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: J Clin Invest. 1992; 90:584-595.
7. Wilson RC, Wei J-Q, Cheng KC, et al: Rapid deoxyribonucleic acid analysis by allele -specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab. 1995; 80:1635-1640.
8. Speiser PW, Laforgia N, Kato K, et al: First trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia(21-hydroxylase deficiency). [Review]. J Clin Endocrinol Metab. 1990; 70:838-848.
9. David M, Forest MG:Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr. 1984; 105:779-803.
10. Evans MI, Chrousos GP, Mann DW, et, al:Pharmacological suppression of the fetal adrenal gland in utero. JAMA. 1985; 253:1015-1020.
11. Forest MG, Betuel H, David M:Traitement antenatal de l'hyoerplasie congenitale des surrenales par deficit en 21-hydroxylase:Etude multicentrique. Ann Endocrinol(Paris). 1987; 48:31-34.
12. Forest MG, Betuel H, David M:Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency:up-date 88 of the French multicentric study. Endocr Res. 1989; 15:277-301.
13. Romer TE, Ginalska-Malinowska M:Successful prenatal treatment of congenital adrenal hyperplasia resulting from the 21-hydroxylase deficiency:Is prenatal diagnosis in a mother at risk essential? Endokrynol Pol. 1987; 38:12-15.
14. Jeffcoate TNA, Fleigner JRH, Russell SH, et al:Diagnosis of the adrenogenial syndrome before birth. Lancet. 1965; 2:553.
15. New MI:Congenital adrenal hyperpalsia, in DeGroot LJ, Besser M, Burger HG, et al.(eds):Endocrinology, 3rd ed. Pennsylvania, W. S. Saunders Company. 1995, pp1813-1835.
16. Miller WL and Tyrrell JB:The adrenal Cortex, in Felig P, Baxter JD and Frohman LA(eds):Endocrinology and Metabolism, 3rd ed. New York, McGraw-Hill, Inc. 1995, pp555-711.
17. Sambrook J, Fritsch EF, Maniatis T:Molecular cloning. A Laboratory Manual 2nd ed. Cold Spring Harbor Laborotary Press, 1989.
18. Miller SA, Dykes DD, Polesky HF:A Single salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215-1219.
19. Higashi Y, Tanae A, Inoue H, et al:Aberrant splicing and missence mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans:possible gene conversion products. Proc Natl Acad Sci USA. 1988; 85:7486-7490.
20．卢圣栋 主编：现在分子生物学实验技术．高等教育出版社，1993．p209．
21. White PC, Vitek A, Dupont B, et al:Characterization of frequent deletion causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA. 1988; 85:4436-4440.
22. White PC:Analysis of mutations causing steroid 21-hydroxylase deficiency. Endocr Res. 1989; 15:239-256.
23. Speiser PW, Dupont J, Zhu D, et al:Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992; 90:594-595.
24. Chomozynski P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Analytical Biochem. 1992; 201:134-139.
25．潘星时，陈磊，陈中孚，等：正常人及先天性肾上腺皮质增生症患者21-羟化酶基因的变异研究．中华医学杂志．1991；71：318-320．
26. Wilson RC, Mercado AB, Cheng KC, et al:Steroid 21 hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 80:2322-2329, 1995.
27. Wedell AA, Thilen A, Ritzen EM, et al: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab. 1994; 78:1145-1152.
28. Speiser PW, White PC, Dupont J,et al: Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency by allele-specific hybridization and southern blot. Hum Genet. 1994; 93:424-428.
29. Higashi Y, et al: Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450 (C21) gene: implication for steroid 21-hydroxylase deficiency. Am J Hum Genet. 1988; 42:17.
30. Morel Y, Murena M, Nicolino M, et al: Correlation between genetic leasions of the CYP21B gene and the clinical forms of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: report of a large study of 355 CAH chromosomes. Horm Res. 1992; 37:13.
31. Mornet E, Crete P, Kuttenn F, et al: Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet. 1991; 48:79- 88.
32. Higashi Y, Hiromasa T, Tanae A, et al: Effects of individual mutations in the P-450 (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem. 1991; 109:638-644.
33. Partanen J, Koskimies S, Sipila I, et al: Major-histo-compatibility- complex gene markers and restriction fragment analysis of steroid 21-hydroxylase (CYP21) and complement C4 genes in classical congenital adrenal hyperplasia patients in a single population. Am J Hum Genet. 1989; 44:660-670.
34. Tusie-Luna M.-T., Speiser PW, Dumic M., et al: A mutation (Pro-30 to Leu-30) in CYP21 represents a potential nonclassic steroid 21 -hydroxylase deficiency allele. Molec Endocr 5:685, 1991.
35. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21 -hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 265:20916-20922, 1990.
1. Sydnor KL, Kelley VC, Raile RB, et al: Blood adrenocorticotropin in children with congenital adrenal hyperplasia. Proc Soc Exp Biol Med 82:695,1953.
2. Binoux M, Pham-Huu-Trung MT, Gourmelen M, et al: Plasma ACTH in adrenogenital syndrome. Acta Paediatr Scand. 1972; 61:269.
3. Ganong WF, Alpert LC, Lee TC: ACTH and the regulation of adrenocortical secretion. N Engl J Med. 1974; 290:1006.
4. New MI, White PC, Pang S, Dupont B, Speiser PW: The adrenal hyperplasia, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th Ed. New York, McGraw-Hill, 1989, pp1881-1917.
5. Pang S, Wallace MA, Hofman L, et al: Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988; 81:866-874.
6. Pang S, Murphey W, Levine LS: A pilot newborn screening for congenital adrenal hyperplasia (CAH) in Alaska. Pediatr Res. 1981; 15:512.
7. Speiser PW, Dupont B, Rubinstein P, et al: High frequency of nonclassical steroid 21 -hydroxylase deficiency. Am J Hum Genet. 1985; 37:650.
8. Aguilera G, Cart KJ: Regulation of aldosterone secretion by the renin-angiotensin system. Proc Natl Acad Sci USA. 1978; 75:4057.
9. Finkelstein M, Schaefer JM: Inborn errors of steroid biosynthesis. Physilo Rev. 1979; 59:353.
10. New MI, Levine LS: Congenital adrenal hyperplasia, in Harris H, Hirschhorn k (eds): Advances in Human Genetics. New York, Plenum, 1973,pp326.
11. Lambeth JD, Stevens VL: Cytochrome P-450scc: Enzymology, and the regulation of intramitochondrial cholesterol delivery to the enzyme. Endocrine Res. 1985; 10:283.
12. Kowarski A, Finkelstein JW, Spaulding JS, et al: Aldosterone secretion rate in congenital adrenal hyperplasia: A discussion of the theories on the pathogenesis of the salt-losing form of the syndrome. J Clin Invest. 1965; 44:1505.
13. Godard C, Riondel AM, Veyrat R, et al: Plasma renin activity and aldosterone secretion in congenital adrenal hyperplasia. Pediatrics. 1968; 41:883.
14. Simopoulos AP, Marshall JR, Delea CS, et al: Studies on the deficiency of 21 -hydroxylation in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1971; 32:438.
15. Strickland AL, Kotchen TA: A study of the renin-aldosterone system in congenital adrenal hyperplasia. J Pediatr. 1972; 81:962.
16. Dillon MJ: Plasma renin activity and aldosterone concentration in children: Results in salt-wasting states. Arch Dis Child. 1975; 50:330.
17. Edwin C, Lanes R, Migeon CJ, et al: Persistence of the enzymatic block in adolescent patients with salt-losing congenital adrenal hyperplasia. J Pediatr. 1979; 95:534.
18. Rosier A, Levine LS, Schneider B, et al: The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977; 45:500.
19. Kuhnle U, Rosier A, Pareira JA, et al: The effects of long term normalization of sodium balance on linear growth in disorders with aldosterone deficiency. Acta Endocrinol. 1983; 102:577.
20. Kominami S, Ochi H, Kobayashi Y, et al: Studies on the steroid hydroxylation system in adrenal cortex microsomes: Purification and characterization of cytochrome P-450 specific for steroid C-21 hydroxylation. J Bio Chem. 1980; 255:3386.
21. Moller G (ed): Molecular genetics of Class III MHC antigens. Immunol Rev. 1985; 87:1.
22. White PC, New MI, Dupont B: Structure of human steroid 21- hydroxylase gene. Proc Natl Acad Sci USA. 1986; 83:5111-5115.
23. Higashi Y, Yoshioka H, Yamane M, et al: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudogene and a genuine gene. Proc Nail Acad Sci USA. 1986; 83:2841-2845.
24. Spence MA, Tsui LC: Report of the committee on the genetic constitution of chromosomes 7, 8 and 9, in Human Gene Mapping 9. Ninth International Workshop on Human Gene Mapping (Cytogenet Cell Genet, vol 46). Basel, Karger, 1987, pp170.
25. Dupont B, Oberfield SE, Smithwick EM, et al: Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet. 1977; 2:1309.
26. Levine LS, Zachmann M, New MI, et al: Genetic mapping of the 21-hydroxylase deficiency gene within the HLA linkage group. N Engl J Med 1978; 299:911.
27. New MI: HLA and adrenal disease, in Farid NR (ed): Immunogenetics of Endocrine Disorders, 2d ed. New York, Alan R. Liss, 1988, pp 309.
28. Awdeh ZL, Raum D, Yunis EJ, et al: Extended HLA/complement allele haplotypes: Evidence for T/t-like complex in man. Proc Natl Acad Sci USA. 1983; 80:259.
29. Klouda PT, Harris R, Price DA: Linkage and association between HLA and 21-hydroxylase deficiency. J Med Genet. 1980; 17:337.
30. Dupont B, Virdis R, Lerner AJ, et al: Distinct HLA-B antigen association for the salt-wasting and simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, in Albert ED, Baur MP, Mayr WR (eds): Histocompatibility Testing 1984. Berlin, Springer-Verlag, 1984, pp 660.
31. Fleischnick E, Raum D, Alosco SM, et al: Extended MHC haplotypes in 21-hydroxylase deficiency congenital adrenal hyperplasia. Lancet. 1983; 1:152.
32. O'Neill GL, Dupont B, Pollack MS, et al: Complement C4 allotypes in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Further evidence for different allelic variants at the 21-hydroxylase locus. Clin Immunol Immunopathol. 1982; 23:312.
33. Raum DW, Awdeh ZL, Anderson J, et al: Human C4 haplotypes with duplicated C4A or C4B. Am J Hum Genet. 1984; 36:72.
34. Carroll MC, Campbell RD, Porter RR: Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA. 1985; 82:521.
35. Werkmeister JW, New MI, Dupont B, et al:Frequent deletion and duplication of the steroid 21-hydroxylase genes. Am J Hum Genet. 1986; 39:461.
36. Rumsby G, Carroll MC, Porter RR, et al:Deletion of the Steroid 21-hydroxylase and complement C4 genes in congenital adrenal hyperplasia. J Med Genet. 1986; 23:204.
37. Globerman H, Amor M, New MI, et al:A nonsense mutation causing steroid 21-hydroxylase deficiency. Program and Abstracts, Bat-Sheva Seminar on Molecular Approaches to Hormone Action, Tiberias, Israel, October 1987.
38. Rodrigues NR, Dunham I, Yu C-Y, et al:Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J. 1987; 6:1653.
39. Donohoue PA, Jospe N, Migeon CJ, et al:Restriction maps and restriction fragment length polymorphisms of the human 21-hydroxylase genes. Biochem Biophys Res Commun. 1986; 130:722.
40. White PC, Grossberger D, Onufer BJ, et al:Two genes encoding steroid 21-hydroxylase are located near the fourth component of complement. Proc Natl Acad Sci USA. 1985; 82:1089.
41. Chung BC, Matteson KJ, Miller WL:Structure of a bovine gene for P-450c21(steroid 21-hydroxylase) defines a novel cytochrome P-450 gene family. Proc Natl Acad Sci USA. 1986; 83:4243.
42. Rodgigues NR, Dunham I, Yu CY, et al:Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J. 1987; 6:1653.
43. Donohoue PA, Sandrini-Neto R, Collin MM, et al: Exon 7 Ncol restriction site within CYP21B (steroid 21-hydroxylase) is a normal polymorphism. Mol Endocrinol. 1990; 4:1354.
44. Wilson RC, Mercado AB, Cheng KC, et al: Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab. 1995; 80:2322-2329.
45. Stoner E, Dimartino J, Kuhnle U, et al: Is salt wasting in congenital adrenal hyperplasia genetic? Clin Endocrinol. 1986; 24:9.
46. Luetscher JA: Studies of aldosterone in relation to water and electrobalance in man. Recent Prog Horm Res. 1956; 12:175.
47. Urban MD, Lee PA, Migeon CJ: Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Eng J Med. 1978; 299:1392.
48. Pang S, Lerner AJ, Stoner E, et al: Late-onset adrenal steroid 3β-hydroxysteroid dehydrogenase deficiency. A cause of hirsutism in pubertal and postpubertal women. J Clin Endocrinol Metab. 1985; 60:428.
49. Child DF, Bu'Lock DE, Anderson DC: Adrenal steroidogenesis in hirsute women. Clin Endocrinol. 1980; 12:595.
50. Gibson M, Lackritz R, Schiff I, et al: Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertil Steril. 1980; 33:43.
51. Lobo RA, Gobelsmann U: Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. Am J Obstet Gynecol. 1980; 138:720.
52. Chrousos GP, Loriaux DL, Mann DL, et al: Late-onset 21- hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. A allelic variant of congenital virilizing adrenal hyperplasia with a milder enzymatic defect. Ann Intern Med. 1982; 96:143.
53. Chrousos GP, Loriaux DL, Mann D, et al: Late-onset 21-hydroxylase deficiency is an allelic variant of congenital adrenal hyperplasia characterized by attenuated clinical expression and different HLA haplotype association. Horm Res. 1982; 16: 193.
54. Chetkowski R, Defazio J, Shamonki I, et al: The incidence of Late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women. . J Clin Endocrinol Metab. 1984; 58:595.
55. Kuttenn F, Couillin P, Girard F, et al: Late-onset adrenal hyperplasia in hirsutism. N Engl J Med. 1986; 313:224.
56. Zerah M, Pang S, New MI: Morning salivary 17- hydroxyprogesterone is a useful screening test for nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1987; 65:227.
57. Kuttenn F: Late-onset adrenal hyperplasia (letter). N Engl J Med. 1986; 314:450.
58. New MI, Lorenzen F, Lerner AJ, et al: Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab. 1987; 65:227.
59. Tusie-Luna M.-T., Speiser PW, Dumic M., et al: A mutation (Pro-30 to Leu-30) in CYP21 represents a potential nonclassic steroid 21 -hydroxylase deficiency allele. Molec Endocr. 1991; 5:685.
60. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem. 1990; 265:20916-20922.
61. Wu DA, Chung BC: Mutations of P450c21 (steroid 21- hydroxylase) at Cys428, Val281 and Ser268 result in complete, partial or no loss of enzymatic activity, respectively. J Clin Invest. 1991; 88:519-523.
62. Higashi Y, Hiromasa T, Tanae, et al: Effects of individual mutations in the P-450c21 pseudogene on the P-450c21 activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem. 1991; 109:638-644.
63. Speiser PW, Dupont J, Zhu D, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992; 90:594-595.
64. Wilkins L, Lewis RA, Klein R, et al: The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp. 1950; 86:249.
65. Bartter FC: Adrenogenital syndromes from physiology to chemistry (1950-1975), in Lee PA, Plotnick LP, Kowarski AA, et al (eds): Congenital Adrenal Hyperplasia. Baltimore, University Park Press, 1977, pp9.
66. Winter JSD: Maximal comment: Current approaches to the treatment of congenital adrenal hyperplasia. J Pediatr. 1980; 97:81.
67. Korth-Schutz S, Virdis R, Saenger p, et al: Serum androgens as a continuing index of adequacy of treatment of congenital adrenal hyperplasia . J Clin Endocrinol Metab. 1978; 46:452.
68. Golden MP, Lippe BM, Kaplan SA, et, al: Management of congenital adrenal hyperplasia using serum dehydroepiandrosterone sulfate and 17-hydroxyprogesterone concentrations. Pediatrics. 1978; 61:867.
69. Winterer J, Chrousos GP, Loriaux DL, et al: Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. J Pediatr. 1985; 106:137.
70. Migeon CJ, Donohoue PA: Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: Its molecular basis and its remaining therapeutic problems. Endocrinol Metab Clin Nor Am. 1991; 30:277-296.
71. Money J, Schwartz M: Dating, romantic and nonromantic friendships, and sexuality in 17 early-treated adrenogenital females, ages 16-25. In Lee PA, Plotnick LP, Kowarski AA, et al (eds): Congenital Adrenal Hyperplasia. Baltimore, University Park Press, 1977,pp419.
72. Money J, Schwartz M, Lewis VG: Adult erotosexual status and fetal hormonal masculinization and demasculinization: 46,XX congenital virilizing adrenal hyperplasia and 46,XY androgen- insensitivity syndrome compared. Psychoneuroendocrinology. 1984; 9:405.
73. Mulaikal R, Migeon CJ, Rock JA: Fertility rate in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 1987; 316:178.
74. Baker SW: Psychological management of intersex children, in Josso N (ed): The Intersex Child (Pediatr Adolesc Endocronol, Vol 8). Basel, Karger, 1981, pp261.
75. Jeffcoate TNA, Fleigner JRH, Russell SH, et al: Diagnosis of the adrenogenial syndrome before birth. Lancet. 1965; 2:553.
76. Levine LS: Prenatal detection of congenital adrenal hyperplasia, in Milunsky A (ed): Genetic Disorders and the Fetus. New York, Plenum, 1986, p 369-385.
77. Frasier SD, Thorneycroft IH, Weill BA, et al: Elevated amniotic fluid concentration of 17-hydroxyprogesterone in congenital adrenal hyperplasia. J Pediatr. 1975; 86:310.
78. Nagamani M, McDonough PG, Ellegood JO, et al: Maternal and amniotic fluid 17-hydroxyprogesterone levels during pregnancy: Diagnosis of congenital adrenal hyperplasia in utero. Am J Obstet Gynecol. 1978; 130:791.
79. Hughes IA, Laurence KM: Antenatal diagnosis of congenital adrenal hyperplasia. Lancet. 1979; 2:7.
80. Pang S, Levine LS, Cederqvist LL, et al: Amniotic fluid concentration of △5 and △4 steroids in fetuses with congenital adrenal hyperplasia due to 21-hydroxylase deficiency and in anencephalic fetuses. J Clin Endocrinol Metab. 1980; 51: 223.
81. Hughes IA, Laurence KM: Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Amniotic fluid steroid analysis. Prenat Diagn. 1982; 2:97.
82. Dorche C, Dhoudt SL, Bozon D: Systematic neonatal screening for congenital adrenal hyperplasia. Report of a pilot study in two centers in France, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series). Amsterdam, Elsevier, 1987,pp289.
83. Blankstein J., Fujieda K, Reyes FI, et, al: Cortisol, 11- deoxycortisol and 21-deoxycortisol concentrations in amniotic fluid during normal pregnancy. Am J Obstet Gynecol. 1980; 137:781.
84. Frasier SD, Weiss BA, Horton R: Amniotic fluid testosterone: Implications for the prenatal diagnosis of congenital adrenal hyperplasia. J Pediatric 1974; 84:738.
85. Couillin P, Nicolas H, Boue J et al: HLA typing of amniotic-fluid cells applied to prenatal diagnosis of congenital adrenal hyperplasia. Lancet. 1979; 1:1076.
86. Pollack MS, Levine LS, Pang S, et, al: Prenatal diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency) by HLA typing. Lancet. 1979; 1:1107.
87. Mercado AB, Wilson RC, Cheng KC, et al: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol metab. 1995; 80:2014-2020.
88. Evans MI, Chrousos GP, Mann DW, et, al: Pharmacological suppression of the fetal adrenal gland in utero. JAMA. 1985; 253:1015-1020.
89. Dorr HG, Sippell WG, Haack D, et, al: Pitfalls of prenatal treatment of congenital adrenal hyperplasia (CAH) due to 21- hydroxylase deficiency. Prog and Abstr, 25th Annual Meeting of the European Society for Paediatric Endocrinology. Zurich, August 1986.
90. Forest MG, Betuel H, David M: Traitement antenatal de Phyoerplasie congenitale des surrenales par deficit en 21- hydroxylase: Etude multicentrique. Ann Endocrinol (Paris). 1987; 48:31-34.
91. Goldman AS, Shapior BH, Katsumata MM: Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature. 1978; 272:464.
92. Forest MC, Betuel H, David M: Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: update 88 of the French multicentric study. Endocr Res. 1989; 15:277-301.
93. Forest MC, David M, Morel Y: Prenatal diagnosis and treatment of 21-hydroxylase deficiency (Review). J Steroid Biochem Mol Biol. 1993; 45:75-82,.
94. Pang S, Spence DA, New MI: Newborn screening for congenital adrenal hyperplasia with special reference to screening in Alaska. Ann NY Acad Sci. 1985; 458:90.
95. Cacciari E, Balsamo A, Cassio A, et al: Neonatal screening for congenital adrenal hyperplasia in a homogeneous Caucasian population. Ann NY Acad Sci. 1985; 458:85.
96. Natoli G, Moschini L, Acconcia P, et al: Newborn screening for 21-hydroxylase deficiency. Radioimmunoassay (RIA) of 17α-hydroxyprogesterone by microfilter paper method, in Second International Symposium in Recent Progress in Pediatric Endocrinology (Serono), Milan Oct 22-23,1981. New York, Raven, 1981, pp33.
97. Suwa SY, Shinozawa K, Kitagawa K, et al: Collaborative study on regional neonatal screening for congenital adrenal hyperplasia in Japan, in Therrell BL (ed): Advances in Neonatal Screening, (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp279.
98. Wallace AM, Beastall GH, Kennedy R, et al: Congenital adrenal hyperplasia in 120,000 Scottish neonates, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp293.
99. Lyon I, Webster D, Dance P: Newborn screening for congenital adrenal hyperplasia in New Zealand, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp297.
100.Hofman LF: Screening infants for congenital adrenal hyperplasia: The Washington experience, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp287.
101.Fujieda K, Matsu-Ura N, Takasugi N, et al: Five years' experience of newborn screening program for congenital adrenal hyperplasia in Sapporo, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp281.
102.Childs B, Grumbach MM, Van Wyk JJ: Virilizing adrenal hyperplasia: genetic and hormonal study. J Clin Invest. 1956; 35:213-222.
103.Wilkins L: Adrenal disorders. II. Congenital virilizing adrenal hyperplasia. Arch Dis Child. 1962; 37:231-241.
104.Hirschfeld AJ, Fleshman JK: An unusually high incidence of salt- losing congenital adrenal hyperplasia in the Alaskan Eskimo. J Pediatr. 1969; 75:492-494.
105.Qazi QH, Thompson MW: Incidence of salt-wasting form of congenital virilizing adrenal hyperplasia. Arch Dis Child. 1972; 47:302-304.
106.Prader A: Die Haufigkeit des kongenitalen adrenogenitalen Syndromes. Helv Paediatr Acta. 1958; 13:426.
107.Prader A, Anders G, Habich H: Zur Genetik des kongenitalen adrenogenitalen Syndromes (virilisierende Nebennierenhyperplasie). Helv Paediatr Acta. 1962; 17:271.
108.Hubble D: Congenital adrenal hyperplasia, in Holt KS, Raine DN (eds): Basic Concepts of Inborn Errors and Defects of Steroid Biosynthesis. Edinburgh, Livingston, 1966, pp68.
109.Mauthe I, Laspe H, Knorr D: Zur Haufigkeit des kongenitalen adrenogenitalen Syndromes (AGS): Munchen 1963-1972. Klin Padiatr. 1977; 189:172.
110.Rosenbloom AL, Smith DW: Congenital adrenal hyperplasia. Lancet. 1966; 1:660.
111.Bois E, Mornet E, Chompret A, et al: L'hyperplasie congenitale des surrenales (21-OH) en France. Arch Fr Ped 1985; 42:175.
112.Muller W, Prader A, Kofler J, et al: Frequency of congenital adrenal hyperplasia. Pediatr Padol. 1979; 14:151.
113.Werder EA, Siebenmann RE, Knorr-Murset G, et al: The incidence of congenital adrenal hyperplasia in Switzerland-A survey of patients in 1960 to 1974. Helv paediatr Acta. 1980; 35:5.
114.Wallace AM, Beastall GH, Cook B, et al: Neonatal screening for congenital adrenal hyperplasia: A programme based on a novel direct radioimmunoassay for 17-hydroxyprogesterone in blood spots. J Endocrinol. 1986; 108:299-308.
115.Suw SY, Igarashi I, Kato K, et al: A case survey study for congenital adrenal hyperplasia in Japan. 1. Study for incidence. Acta Paediatr Jap. 1981; 85:204.
116.Wilkins L: The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, 3rd ed. Springfield, Charles C Thomas, 1965, pp401-427.
117.Thuline HC: Newborn screening for congenital adrenal hyperplasia (CAH), in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp301.
118.Cavalli-Sforza LL, Bodmer WR: The Genetics of Human Populations. San Francisco, WH Freeman, 1971.
119.Raiti S, Newns GH: Congenital adrenal hyperplasia. Arch Dis Child 1964; 39:324-333.
120.Kowarski AA: Mechanism of salt lose in congenital virilizing adrenal hyperplasia, in Lee PA, Plotnick LP, Kowarski AA, Migeon CJ (eds): Congenital Adrenal Hyperplasia. Baltimore, University Park Press, 1977, pp114.
121.Migeon CJ: Diagnosis and treatment of adrenogenital disorders, in De-Groot LJ, Cahill GF Jr, Odell WD, et al (eds): Endocrinology. New York, Grune & Stratton, 1979, pp1204.
122.Bondy PK: The adrenal cortex, in Bondy PK, Rosenberg LE (eds): Metabolic Control and Disease, Philadelphia, Saunders, 1980, pp1482.
123.Fife D, Rappaport EB: Prevalence of salt losing among congenital adrenal hyperplasia patients. Clin Endocrinol 1983; 19:259-264.
124.Pang S, Hotchkiss J, Drash AL, et al: Microfilter paper method for 17α-progesterone radioimmunoassay:Its application for rapid screening for congenital adrenal hyperplasia, J Clin Endocrinol Metab 1977; 45:1003.
125. New MI:21-hydroxylase deficiency congenital adrenal hyperplasia. J Steroid Biochem Molec Biol. 1994; 48:15-22.
126. Owerbach D, Crawford YM, Draznin MB. Direct analysis of CYP21B genes in 21-hydroxylase deficiency using polymerase chain reaction amplification. Mol Endocrinol. 1990; 4:125-131.
127. Wilson RC, Wei J-Q, Cheng KC, et al:Rapid deoxyribonucleic acid analysis by allele-specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase genes, J Clin Endocrinol Metab. 1995; 80:1635-1640.
128. New MI:Congenital adrenal hyperpalsia, in DeGroot LJ, Besser M, Burger HG, et al.(eds):Endocrinology, 3rd ed, Pennsylvania, W. S. Saunders Company. 1995, pp1813-1835.
129. Miller WL and Tyrrell JB:The adrenal Cortex, in Felig P, Baxter JD and Frohman LA(eds):Endocrinology and Metabolism, 3rd ed. New York, McGraw-Hill, Inc. 1995, pp555-711.
2. Binoux M, Pham-Huu-Trung MT, Gourmelen M, et al: Plasma ACTH in adrenogenital syndrome. Acta Paediatr Scand. 1972; 61:269.
3. Ganong WF, Alpert LC, Lee TC: ACTH and the regulation of adrenocortical secretion. N Engl J Med. 1974; 290:1006.
4. New MI, White PC, Pang S, Dupont B, Speiser PW: The adrenal hyperplasia. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th Ed. New York, McGraw-Hill. 1989, ppl881-1917.
5. Pang S, Wallace MA, Hofman L, et al: Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988; 81:866-874.
6. Pang S, Murphey W, Levine LS: A pilot newborn screening for congenital adrenal hyperplasia (CAH) in Alaska. Pediatr Res. 1981; 15:512.
7. New MI: Congenital adrenal hyperpalsia. In DeGroot LJ, Besser M, Burger HG, et al. (eds): Endocrinology, 3rd ed. Pennsylvania, W.S. Saunders Company. 1995, ppl813-1835.
8. Miller WL and Tyrrell JB: The adrenal Cortex, in Felig P, Baxter JD and Frohman LA (eds): Endocrinology and Metabolism, 3rd ed. New York, McGraw-Hill, Inc.. 1995, pp555-711.
9. Tusie-Luna M.-T., Speiser PW, Dumic M., et al: A mutation (Pro-30 to Leu-30) in CYP21 represents a potential nonclassic steroid 21- hydroxylase deficiency allele. Molec Endocr. 1991; 5:685.
10. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem. 1990; 265:20916-20922.
11. Wu DA, Chung BC: Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281 and Ser268 result in complete, partial or no loss of enzymatic activity, respectively. J Clin Invest. 1991; 88:519-523.
12. Marshall WA and Tanner JM: Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44:291 -301.
13. Van Wieringen JC, Wafelbakker F, Verbugge HP, et al: Growth Diagrams 1965 Netherlands: Second national survey on 0-24 year olds. Netherlands Institute for Preventive Medicine TNO Leiden, Wolters-Noordhoff Publishing, Groningen, 1971.
14. Reynolds EL and Wines JV: Individual differences in physical changes associated with adolescence in girls. Am J Dis Child. 1948; 75:329.
15. Dupertuis CW, Atkinson WB and Elftman H: Sex differences in pubic hair distribution. Hum Biol. 1945; 17:137.
16. Marshall WA and. Timer JM: Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970; 45:13-23.
17. Reynolds EL and Wines JV: Physical changes associated with adolescence in boys. Am J Dis Child. 1951; 82: 29.
18. Prader A: Die haufigkeit der kongenitalen adrenogenitalen syndromes. Helv Paediatr Acta. 1958; 13: 5.
19. Kaplan SL and Grumbach MM: Pathophysiology and treatment of sexual precocity. J Clin Ehdocrinol Metab. 1990; 71: 785.
20. Nicholson AB and Hanley C: Indices of physiological maturity: Derivation and interrelationships. Child Dev. 1953; 24: 3.
21. Zacharias L, Rand WM and Wurtman RJ: A prospective study of sexual development in American girls: The statistics of menarche. Obstet Gynecol Surv. 1976; 31: 325.
22. Styne DM and Grumbach MM: Puberty in the male and female: Its physiology and disorders. In Samuel S. C. Yen and Robert B. Jaffe(eds): Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 2nd Ed. Pennsylvania, W. S. Saunders Company. 1986, pp313-384.
23. Root AW and Reiter ED: Evaluation and management of the child with delayed pubertal development. Fertil Steril. 1976; 27: 745-755.
24．池芝盛等(编译)：内分泌学基础与临床．北京科学技术出版社．1992，pp491．
25. New MI, Gertner JM, Speiser PW, et al: Growth and final height in classic and nonclassic 21-hydroxylase deficiency. Acta Paediatr Jpn. 1988; 30(suppl): 79-88.
26. Miller WL: The adrenal Cortex. In Rudolph AM, Hoffman JIE, Rudolph CR(eds): Rudolph's Pediatrics, 19th Ed. Norwalk, Conn., Appleton & Lange. 1991, pp 1584.
27. Klingensmith JG, Garcia SC, Jones HW Jr, et al: Glucocorticoid treatment of girls with congenital adrenal hyperplasia: Effects on height, sexual matuation and fertility. J Pediatr. 1977; 90: 996.
28. Mulaikal R, Migeon CJ, Rock JA: Fertility rates in female patients with congenital hyperplasia due to 21-hydroxylase dficiency. N Engl J Med. 1987; 316: 178.
29. Migeon CJ and Donohoue PA: Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: Its molecular basis and its remaining therapeutic problems, in Nelson DH(ed): Endocrinology and Metabolism Clinics of North America: New Concept of Adrenal Disease. Endocrinol Metab Clin Nor Am. 1991; 20(2): 277-296.
30. Wilson RC, Mercado AB, Cheng KC, et al: Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab. 1995; 80: 2322-2329.
31．竹田亮佑，森本真本，宫森勇等：醛固酮是从肾上腺皮质球状带分泌的最强的盐皮质激素．综合临床．1978；27(suppl)：332-337．
1. New MI, White PC, Pang S, Dupont B, Speiser PW: The adrenal hyperplasia, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th Ed. New York, McGraw-Hill, 1989, pl881-1917.
2. Pang S, Wallace MA, Hofman L, et al: Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988; 81:866-874.
3. White PC, New MI, Dupont B: Structure of human steroid 21- hydroxylase gene. Proc Natl Acad Sci USA. 1986; 83:5111 -5115.
4. Higashi Y, Yoshioka H, Yamane M, et al: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudogene and a genuine gene. Proc NatlA cad Sci USA. 1986; 83:2841-2845.
5. Mercado AB, Wilson RC, et al: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol metab. 1995; 80: 2014-2020.
6. Speiser PW, Dupont J, Zhu D, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: J Clin Invest. 1992; 90:584-595.
7. Wilson RC, Wei J-Q, Cheng KC, et al: Rapid deoxyribonucleic acid analysis by allele -specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase gene. J Clin Endocrinol Metab. 1995; 80:1635-1640.
8. Speiser PW, Laforgia N, Kato K, et al: First trimester prenatal treatment and molecular genetic diagnosis of congenital adrenal hyperplasia(21-hydroxylase deficiency). [Review]. J Clin Endocrinol Metab. 1990; 70:838-848.
9. David M, Forest MG:Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr. 1984; 105:779-803.
10. Evans MI, Chrousos GP, Mann DW, et, al:Pharmacological suppression of the fetal adrenal gland in utero. JAMA. 1985; 253:1015-1020.
11. Forest MG, Betuel H, David M:Traitement antenatal de l'hyoerplasie congenitale des surrenales par deficit en 21-hydroxylase:Etude multicentrique. Ann Endocrinol(Paris). 1987; 48:31-34.
12. Forest MG, Betuel H, David M:Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency:up-date 88 of the French multicentric study. Endocr Res. 1989; 15:277-301.
13. Romer TE, Ginalska-Malinowska M:Successful prenatal treatment of congenital adrenal hyperplasia resulting from the 21-hydroxylase deficiency:Is prenatal diagnosis in a mother at risk essential? Endokrynol Pol. 1987; 38:12-15.
14. Jeffcoate TNA, Fleigner JRH, Russell SH, et al:Diagnosis of the adrenogenial syndrome before birth. Lancet. 1965; 2:553.
15. New MI:Congenital adrenal hyperpalsia, in DeGroot LJ, Besser M, Burger HG, et al.(eds):Endocrinology, 3rd ed. Pennsylvania, W. S. Saunders Company. 1995, pp1813-1835.
16. Miller WL and Tyrrell JB:The adrenal Cortex, in Felig P, Baxter JD and Frohman LA(eds):Endocrinology and Metabolism, 3rd ed. New York, McGraw-Hill, Inc. 1995, pp555-711.
17. Sambrook J, Fritsch EF, Maniatis T:Molecular cloning. A Laboratory Manual 2nd ed. Cold Spring Harbor Laborotary Press, 1989.
18. Miller SA, Dykes DD, Polesky HF:A Single salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215-1219.
19. Higashi Y, Tanae A, Inoue H, et al:Aberrant splicing and missence mutations cause steroid 21-hydroxylase [P-450(C21)] deficiency in humans:possible gene conversion products. Proc Natl Acad Sci USA. 1988; 85:7486-7490.
20．卢圣栋 主编：现在分子生物学实验技术．高等教育出版社，1993．p209．
21. White PC, Vitek A, Dupont B, et al:Characterization of frequent deletion causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA. 1988; 85:4436-4440.
22. White PC:Analysis of mutations causing steroid 21-hydroxylase deficiency. Endocr Res. 1989; 15:239-256.
23. Speiser PW, Dupont J, Zhu D, et al:Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992; 90:594-595.
24. Chomozynski P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Analytical Biochem. 1992; 201:134-139.
25．潘星时，陈磊，陈中孚，等：正常人及先天性肾上腺皮质增生症患者21-羟化酶基因的变异研究．中华医学杂志．1991；71：318-320．
26. Wilson RC, Mercado AB, Cheng KC, et al:Steroid 21 hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 80:2322-2329, 1995.
27. Wedell AA, Thilen A, Ritzen EM, et al: Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. J Clin Endocrinol Metab. 1994; 78:1145-1152.
28. Speiser PW, White PC, Dupont J,et al: Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency by allele-specific hybridization and southern blot. Hum Genet. 1994; 93:424-428.
29. Higashi Y, et al: Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450 (C21) gene: implication for steroid 21-hydroxylase deficiency. Am J Hum Genet. 1988; 42:17.
30. Morel Y, Murena M, Nicolino M, et al: Correlation between genetic leasions of the CYP21B gene and the clinical forms of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: report of a large study of 355 CAH chromosomes. Horm Res. 1992; 37:13.
31. Mornet E, Crete P, Kuttenn F, et al: Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. Am J Hum Genet. 1991; 48:79- 88.
32. Higashi Y, Hiromasa T, Tanae A, et al: Effects of individual mutations in the P-450 (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem. 1991; 109:638-644.
33. Partanen J, Koskimies S, Sipila I, et al: Major-histo-compatibility- complex gene markers and restriction fragment analysis of steroid 21-hydroxylase (CYP21) and complement C4 genes in classical congenital adrenal hyperplasia patients in a single population. Am J Hum Genet. 1989; 44:660-670.
34. Tusie-Luna M.-T., Speiser PW, Dumic M., et al: A mutation (Pro-30 to Leu-30) in CYP21 represents a potential nonclassic steroid 21 -hydroxylase deficiency allele. Molec Endocr 5:685, 1991.
35. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21 -hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem 265:20916-20922, 1990.
1. Sydnor KL, Kelley VC, Raile RB, et al: Blood adrenocorticotropin in children with congenital adrenal hyperplasia. Proc Soc Exp Biol Med 82:695,1953.
2. Binoux M, Pham-Huu-Trung MT, Gourmelen M, et al: Plasma ACTH in adrenogenital syndrome. Acta Paediatr Scand. 1972; 61:269.
3. Ganong WF, Alpert LC, Lee TC: ACTH and the regulation of adrenocortical secretion. N Engl J Med. 1974; 290:1006.
4. New MI, White PC, Pang S, Dupont B, Speiser PW: The adrenal hyperplasia, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic Basis of Inherited Disease, 6th Ed. New York, McGraw-Hill, 1989, pp1881-1917.
5. Pang S, Wallace MA, Hofman L, et al: Worldwide experience in newborn screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics. 1988; 81:866-874.
6. Pang S, Murphey W, Levine LS: A pilot newborn screening for congenital adrenal hyperplasia (CAH) in Alaska. Pediatr Res. 1981; 15:512.
7. Speiser PW, Dupont B, Rubinstein P, et al: High frequency of nonclassical steroid 21 -hydroxylase deficiency. Am J Hum Genet. 1985; 37:650.
8. Aguilera G, Cart KJ: Regulation of aldosterone secretion by the renin-angiotensin system. Proc Natl Acad Sci USA. 1978; 75:4057.
9. Finkelstein M, Schaefer JM: Inborn errors of steroid biosynthesis. Physilo Rev. 1979; 59:353.
10. New MI, Levine LS: Congenital adrenal hyperplasia, in Harris H, Hirschhorn k (eds): Advances in Human Genetics. New York, Plenum, 1973,pp326.
11. Lambeth JD, Stevens VL: Cytochrome P-450scc: Enzymology, and the regulation of intramitochondrial cholesterol delivery to the enzyme. Endocrine Res. 1985; 10:283.
12. Kowarski A, Finkelstein JW, Spaulding JS, et al: Aldosterone secretion rate in congenital adrenal hyperplasia: A discussion of the theories on the pathogenesis of the salt-losing form of the syndrome. J Clin Invest. 1965; 44:1505.
13. Godard C, Riondel AM, Veyrat R, et al: Plasma renin activity and aldosterone secretion in congenital adrenal hyperplasia. Pediatrics. 1968; 41:883.
14. Simopoulos AP, Marshall JR, Delea CS, et al: Studies on the deficiency of 21 -hydroxylation in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1971; 32:438.
15. Strickland AL, Kotchen TA: A study of the renin-aldosterone system in congenital adrenal hyperplasia. J Pediatr. 1972; 81:962.
16. Dillon MJ: Plasma renin activity and aldosterone concentration in children: Results in salt-wasting states. Arch Dis Child. 1975; 50:330.
17. Edwin C, Lanes R, Migeon CJ, et al: Persistence of the enzymatic block in adolescent patients with salt-losing congenital adrenal hyperplasia. J Pediatr. 1979; 95:534.
18. Rosier A, Levine LS, Schneider B, et al: The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977; 45:500.
19. Kuhnle U, Rosier A, Pareira JA, et al: The effects of long term normalization of sodium balance on linear growth in disorders with aldosterone deficiency. Acta Endocrinol. 1983; 102:577.
20. Kominami S, Ochi H, Kobayashi Y, et al: Studies on the steroid hydroxylation system in adrenal cortex microsomes: Purification and characterization of cytochrome P-450 specific for steroid C-21 hydroxylation. J Bio Chem. 1980; 255:3386.
21. Moller G (ed): Molecular genetics of Class III MHC antigens. Immunol Rev. 1985; 87:1.
22. White PC, New MI, Dupont B: Structure of human steroid 21- hydroxylase gene. Proc Natl Acad Sci USA. 1986; 83:5111-5115.
23. Higashi Y, Yoshioka H, Yamane M, et al: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudogene and a genuine gene. Proc Nail Acad Sci USA. 1986; 83:2841-2845.
24. Spence MA, Tsui LC: Report of the committee on the genetic constitution of chromosomes 7, 8 and 9, in Human Gene Mapping 9. Ninth International Workshop on Human Gene Mapping (Cytogenet Cell Genet, vol 46). Basel, Karger, 1987, pp170.
25. Dupont B, Oberfield SE, Smithwick EM, et al: Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet. 1977; 2:1309.
26. Levine LS, Zachmann M, New MI, et al: Genetic mapping of the 21-hydroxylase deficiency gene within the HLA linkage group. N Engl J Med 1978; 299:911.
27. New MI: HLA and adrenal disease, in Farid NR (ed): Immunogenetics of Endocrine Disorders, 2d ed. New York, Alan R. Liss, 1988, pp 309.
28. Awdeh ZL, Raum D, Yunis EJ, et al: Extended HLA/complement allele haplotypes: Evidence for T/t-like complex in man. Proc Natl Acad Sci USA. 1983; 80:259.
29. Klouda PT, Harris R, Price DA: Linkage and association between HLA and 21-hydroxylase deficiency. J Med Genet. 1980; 17:337.
30. Dupont B, Virdis R, Lerner AJ, et al: Distinct HLA-B antigen association for the salt-wasting and simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, in Albert ED, Baur MP, Mayr WR (eds): Histocompatibility Testing 1984. Berlin, Springer-Verlag, 1984, pp 660.
31. Fleischnick E, Raum D, Alosco SM, et al: Extended MHC haplotypes in 21-hydroxylase deficiency congenital adrenal hyperplasia. Lancet. 1983; 1:152.
32. O'Neill GL, Dupont B, Pollack MS, et al: Complement C4 allotypes in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Further evidence for different allelic variants at the 21-hydroxylase locus. Clin Immunol Immunopathol. 1982; 23:312.
33. Raum DW, Awdeh ZL, Anderson J, et al: Human C4 haplotypes with duplicated C4A or C4B. Am J Hum Genet. 1984; 36:72.
34. Carroll MC, Campbell RD, Porter RR: Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man. Proc Natl Acad Sci USA. 1985; 82:521.
35. Werkmeister JW, New MI, Dupont B, et al:Frequent deletion and duplication of the steroid 21-hydroxylase genes. Am J Hum Genet. 1986; 39:461.
36. Rumsby G, Carroll MC, Porter RR, et al:Deletion of the Steroid 21-hydroxylase and complement C4 genes in congenital adrenal hyperplasia. J Med Genet. 1986; 23:204.
37. Globerman H, Amor M, New MI, et al:A nonsense mutation causing steroid 21-hydroxylase deficiency. Program and Abstracts, Bat-Sheva Seminar on Molecular Approaches to Hormone Action, Tiberias, Israel, October 1987.
38. Rodrigues NR, Dunham I, Yu C-Y, et al:Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J. 1987; 6:1653.
39. Donohoue PA, Jospe N, Migeon CJ, et al:Restriction maps and restriction fragment length polymorphisms of the human 21-hydroxylase genes. Biochem Biophys Res Commun. 1986; 130:722.
40. White PC, Grossberger D, Onufer BJ, et al:Two genes encoding steroid 21-hydroxylase are located near the fourth component of complement. Proc Natl Acad Sci USA. 1985; 82:1089.
41. Chung BC, Matteson KJ, Miller WL:Structure of a bovine gene for P-450c21(steroid 21-hydroxylase) defines a novel cytochrome P-450 gene family. Proc Natl Acad Sci USA. 1986; 83:4243.
42. Rodgigues NR, Dunham I, Yu CY, et al:Molecular characterization of the HLA-linked steroid 21-hydroxylase B gene from an individual with congenital adrenal hyperplasia. EMBO J. 1987; 6:1653.
43. Donohoue PA, Sandrini-Neto R, Collin MM, et al: Exon 7 Ncol restriction site within CYP21B (steroid 21-hydroxylase) is a normal polymorphism. Mol Endocrinol. 1990; 4:1354.
44. Wilson RC, Mercado AB, Cheng KC, et al: Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab. 1995; 80:2322-2329.
45. Stoner E, Dimartino J, Kuhnle U, et al: Is salt wasting in congenital adrenal hyperplasia genetic? Clin Endocrinol. 1986; 24:9.
46. Luetscher JA: Studies of aldosterone in relation to water and electrobalance in man. Recent Prog Horm Res. 1956; 12:175.
47. Urban MD, Lee PA, Migeon CJ: Adult height and fertility in men with congenital virilizing adrenal hyperplasia. N Eng J Med. 1978; 299:1392.
48. Pang S, Lerner AJ, Stoner E, et al: Late-onset adrenal steroid 3β-hydroxysteroid dehydrogenase deficiency. A cause of hirsutism in pubertal and postpubertal women. J Clin Endocrinol Metab. 1985; 60:428.
49. Child DF, Bu'Lock DE, Anderson DC: Adrenal steroidogenesis in hirsute women. Clin Endocrinol. 1980; 12:595.
50. Gibson M, Lackritz R, Schiff I, et al: Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertil Steril. 1980; 33:43.
51. Lobo RA, Gobelsmann U: Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease. Am J Obstet Gynecol. 1980; 138:720.
52. Chrousos GP, Loriaux DL, Mann DL, et al: Late-onset 21- hydroxylase deficiency mimicking idiopathic hirsutism or polycystic ovarian disease. A allelic variant of congenital virilizing adrenal hyperplasia with a milder enzymatic defect. Ann Intern Med. 1982; 96:143.
53. Chrousos GP, Loriaux DL, Mann D, et al: Late-onset 21-hydroxylase deficiency is an allelic variant of congenital adrenal hyperplasia characterized by attenuated clinical expression and different HLA haplotype association. Horm Res. 1982; 16: 193.
54. Chetkowski R, Defazio J, Shamonki I, et al: The incidence of Late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency among hirsute women. . J Clin Endocrinol Metab. 1984; 58:595.
55. Kuttenn F, Couillin P, Girard F, et al: Late-onset adrenal hyperplasia in hirsutism. N Engl J Med. 1986; 313:224.
56. Zerah M, Pang S, New MI: Morning salivary 17- hydroxyprogesterone is a useful screening test for nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1987; 65:227.
57. Kuttenn F: Late-onset adrenal hyperplasia (letter). N Engl J Med. 1986; 314:450.
58. New MI, Lorenzen F, Lerner AJ, et al: Genotyping steroid 21-hydroxylase deficiency: Hormonal reference data. J Clin Endocrinol Metab. 1987; 65:227.
59. Tusie-Luna M.-T., Speiser PW, Dumic M., et al: A mutation (Pro-30 to Leu-30) in CYP21 represents a potential nonclassic steroid 21 -hydroxylase deficiency allele. Molec Endocr. 1991; 5:685.
60. Tusie-Luna M-T, Traktman P, White PC: Determination of functional effects of mutations in the steroid 21-hydroxylase gene (CYP21) using recombinant vaccinia virus. J Biol Chem. 1990; 265:20916-20922.
61. Wu DA, Chung BC: Mutations of P450c21 (steroid 21- hydroxylase) at Cys428, Val281 and Ser268 result in complete, partial or no loss of enzymatic activity, respectively. J Clin Invest. 1991; 88:519-523.
62. Higashi Y, Hiromasa T, Tanae, et al: Effects of individual mutations in the P-450c21 pseudogene on the P-450c21 activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency. J Biochem. 1991; 109:638-644.
63. Speiser PW, Dupont J, Zhu D, et al: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest. 1992; 90:594-595.
64. Wilkins L, Lewis RA, Klein R, et al: The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp. 1950; 86:249.
65. Bartter FC: Adrenogenital syndromes from physiology to chemistry (1950-1975), in Lee PA, Plotnick LP, Kowarski AA, et al (eds): Congenital Adrenal Hyperplasia. Baltimore, University Park Press, 1977, pp9.
66. Winter JSD: Maximal comment: Current approaches to the treatment of congenital adrenal hyperplasia. J Pediatr. 1980; 97:81.
67. Korth-Schutz S, Virdis R, Saenger p, et al: Serum androgens as a continuing index of adequacy of treatment of congenital adrenal hyperplasia . J Clin Endocrinol Metab. 1978; 46:452.
68. Golden MP, Lippe BM, Kaplan SA, et, al: Management of congenital adrenal hyperplasia using serum dehydroepiandrosterone sulfate and 17-hydroxyprogesterone concentrations. Pediatrics. 1978; 61:867.
69. Winterer J, Chrousos GP, Loriaux DL, et al: Effect of hydrocortisone dose schedule on adrenal steroid secretion in congenital adrenal hyperplasia. J Pediatr. 1985; 106:137.
70. Migeon CJ, Donohoue PA: Congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: Its molecular basis and its remaining therapeutic problems. Endocrinol Metab Clin Nor Am. 1991; 30:277-296.
71. Money J, Schwartz M: Dating, romantic and nonromantic friendships, and sexuality in 17 early-treated adrenogenital females, ages 16-25. In Lee PA, Plotnick LP, Kowarski AA, et al (eds): Congenital Adrenal Hyperplasia. Baltimore, University Park Press, 1977,pp419.
72. Money J, Schwartz M, Lewis VG: Adult erotosexual status and fetal hormonal masculinization and demasculinization: 46,XX congenital virilizing adrenal hyperplasia and 46,XY androgen- insensitivity syndrome compared. Psychoneuroendocrinology. 1984; 9:405.
73. Mulaikal R, Migeon CJ, Rock JA: Fertility rate in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 1987; 316:178.
74. Baker SW: Psychological management of intersex children, in Josso N (ed): The Intersex Child (Pediatr Adolesc Endocronol, Vol 8). Basel, Karger, 1981, pp261.
75. Jeffcoate TNA, Fleigner JRH, Russell SH, et al: Diagnosis of the adrenogenial syndrome before birth. Lancet. 1965; 2:553.
76. Levine LS: Prenatal detection of congenital adrenal hyperplasia, in Milunsky A (ed): Genetic Disorders and the Fetus. New York, Plenum, 1986, p 369-385.
77. Frasier SD, Thorneycroft IH, Weill BA, et al: Elevated amniotic fluid concentration of 17-hydroxyprogesterone in congenital adrenal hyperplasia. J Pediatr. 1975; 86:310.
78. Nagamani M, McDonough PG, Ellegood JO, et al: Maternal and amniotic fluid 17-hydroxyprogesterone levels during pregnancy: Diagnosis of congenital adrenal hyperplasia in utero. Am J Obstet Gynecol. 1978; 130:791.
79. Hughes IA, Laurence KM: Antenatal diagnosis of congenital adrenal hyperplasia. Lancet. 1979; 2:7.
80. Pang S, Levine LS, Cederqvist LL, et al: Amniotic fluid concentration of △5 and △4 steroids in fetuses with congenital adrenal hyperplasia due to 21-hydroxylase deficiency and in anencephalic fetuses. J Clin Endocrinol Metab. 1980; 51: 223.
81. Hughes IA, Laurence KM: Prenatal diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Amniotic fluid steroid analysis. Prenat Diagn. 1982; 2:97.
82. Dorche C, Dhoudt SL, Bozon D: Systematic neonatal screening for congenital adrenal hyperplasia. Report of a pilot study in two centers in France, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series). Amsterdam, Elsevier, 1987,pp289.
83. Blankstein J., Fujieda K, Reyes FI, et, al: Cortisol, 11- deoxycortisol and 21-deoxycortisol concentrations in amniotic fluid during normal pregnancy. Am J Obstet Gynecol. 1980; 137:781.
84. Frasier SD, Weiss BA, Horton R: Amniotic fluid testosterone: Implications for the prenatal diagnosis of congenital adrenal hyperplasia. J Pediatric 1974; 84:738.
85. Couillin P, Nicolas H, Boue J et al: HLA typing of amniotic-fluid cells applied to prenatal diagnosis of congenital adrenal hyperplasia. Lancet. 1979; 1:1076.
86. Pollack MS, Levine LS, Pang S, et, al: Prenatal diagnosis of congenital adrenal hyperplasia (21-hydroxylase deficiency) by HLA typing. Lancet. 1979; 1:1107.
87. Mercado AB, Wilson RC, Cheng KC, et al: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol metab. 1995; 80:2014-2020.
88. Evans MI, Chrousos GP, Mann DW, et, al: Pharmacological suppression of the fetal adrenal gland in utero. JAMA. 1985; 253:1015-1020.
89. Dorr HG, Sippell WG, Haack D, et, al: Pitfalls of prenatal treatment of congenital adrenal hyperplasia (CAH) due to 21- hydroxylase deficiency. Prog and Abstr, 25th Annual Meeting of the European Society for Paediatric Endocrinology. Zurich, August 1986.
90. Forest MG, Betuel H, David M: Traitement antenatal de Phyoerplasie congenitale des surrenales par deficit en 21- hydroxylase: Etude multicentrique. Ann Endocrinol (Paris). 1987; 48:31-34.
91. Goldman AS, Shapior BH, Katsumata MM: Human foetal palatal corticoid receptors and teratogens for cleft palate. Nature. 1978; 272:464.
92. Forest MC, Betuel H, David M: Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: update 88 of the French multicentric study. Endocr Res. 1989; 15:277-301.
93. Forest MC, David M, Morel Y: Prenatal diagnosis and treatment of 21-hydroxylase deficiency (Review). J Steroid Biochem Mol Biol. 1993; 45:75-82,.
94. Pang S, Spence DA, New MI: Newborn screening for congenital adrenal hyperplasia with special reference to screening in Alaska. Ann NY Acad Sci. 1985; 458:90.
95. Cacciari E, Balsamo A, Cassio A, et al: Neonatal screening for congenital adrenal hyperplasia in a homogeneous Caucasian population. Ann NY Acad Sci. 1985; 458:85.
96. Natoli G, Moschini L, Acconcia P, et al: Newborn screening for 21-hydroxylase deficiency. Radioimmunoassay (RIA) of 17α-hydroxyprogesterone by microfilter paper method, in Second International Symposium in Recent Progress in Pediatric Endocrinology (Serono), Milan Oct 22-23,1981. New York, Raven, 1981, pp33.
97. Suwa SY, Shinozawa K, Kitagawa K, et al: Collaborative study on regional neonatal screening for congenital adrenal hyperplasia in Japan, in Therrell BL (ed): Advances in Neonatal Screening, (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp279.
98. Wallace AM, Beastall GH, Kennedy R, et al: Congenital adrenal hyperplasia in 120,000 Scottish neonates, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp293.
99. Lyon I, Webster D, Dance P: Newborn screening for congenital adrenal hyperplasia in New Zealand, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp297.
100.Hofman LF: Screening infants for congenital adrenal hyperplasia: The Washington experience, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp287.
101.Fujieda K, Matsu-Ura N, Takasugi N, et al: Five years' experience of newborn screening program for congenital adrenal hyperplasia in Sapporo, in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp281.
102.Childs B, Grumbach MM, Van Wyk JJ: Virilizing adrenal hyperplasia: genetic and hormonal study. J Clin Invest. 1956; 35:213-222.
103.Wilkins L: Adrenal disorders. II. Congenital virilizing adrenal hyperplasia. Arch Dis Child. 1962; 37:231-241.
104.Hirschfeld AJ, Fleshman JK: An unusually high incidence of salt- losing congenital adrenal hyperplasia in the Alaskan Eskimo. J Pediatr. 1969; 75:492-494.
105.Qazi QH, Thompson MW: Incidence of salt-wasting form of congenital virilizing adrenal hyperplasia. Arch Dis Child. 1972; 47:302-304.
106.Prader A: Die Haufigkeit des kongenitalen adrenogenitalen Syndromes. Helv Paediatr Acta. 1958; 13:426.
107.Prader A, Anders G, Habich H: Zur Genetik des kongenitalen adrenogenitalen Syndromes (virilisierende Nebennierenhyperplasie). Helv Paediatr Acta. 1962; 17:271.
108.Hubble D: Congenital adrenal hyperplasia, in Holt KS, Raine DN (eds): Basic Concepts of Inborn Errors and Defects of Steroid Biosynthesis. Edinburgh, Livingston, 1966, pp68.
109.Mauthe I, Laspe H, Knorr D: Zur Haufigkeit des kongenitalen adrenogenitalen Syndromes (AGS): Munchen 1963-1972. Klin Padiatr. 1977; 189:172.
110.Rosenbloom AL, Smith DW: Congenital adrenal hyperplasia. Lancet. 1966; 1:660.
111.Bois E, Mornet E, Chompret A, et al: L'hyperplasie congenitale des surrenales (21-OH) en France. Arch Fr Ped 1985; 42:175.
112.Muller W, Prader A, Kofler J, et al: Frequency of congenital adrenal hyperplasia. Pediatr Padol. 1979; 14:151.
113.Werder EA, Siebenmann RE, Knorr-Murset G, et al: The incidence of congenital adrenal hyperplasia in Switzerland-A survey of patients in 1960 to 1974. Helv paediatr Acta. 1980; 35:5.
114.Wallace AM, Beastall GH, Cook B, et al: Neonatal screening for congenital adrenal hyperplasia: A programme based on a novel direct radioimmunoassay for 17-hydroxyprogesterone in blood spots. J Endocrinol. 1986; 108:299-308.
115.Suw SY, Igarashi I, Kato K, et al: A case survey study for congenital adrenal hyperplasia in Japan. 1. Study for incidence. Acta Paediatr Jap. 1981; 85:204.
116.Wilkins L: The Diagnosis and Treatment of Endocrine Disorders in Childhood and Adolescence, 3rd ed. Springfield, Charles C Thomas, 1965, pp401-427.
117.Thuline HC: Newborn screening for congenital adrenal hyperplasia (CAH), in Therrell BL (ed): Advances in Neonatal Screening (Excerpta Medica Intl Congr Series, vol 741). Amsterdam, Elsevier, 1987, pp301.
118.Cavalli-Sforza LL, Bodmer WR: The Genetics of Human Populations. San Francisco, WH Freeman, 1971.
119.Raiti S, Newns GH: Congenital adrenal hyperplasia. Arch Dis Child 1964; 39:324-333.
120.Kowarski AA: Mechanism of salt lose in congenital virilizing adrenal hyperplasia, in Lee PA, Plotnick LP, Kowarski AA, Migeon CJ (eds): Congenital Adrenal Hyperplasia. Baltimore, University Park Press, 1977, pp114.
121.Migeon CJ: Diagnosis and treatment of adrenogenital disorders, in De-Groot LJ, Cahill GF Jr, Odell WD, et al (eds): Endocrinology. New York, Grune & Stratton, 1979, pp1204.
122.Bondy PK: The adrenal cortex, in Bondy PK, Rosenberg LE (eds): Metabolic Control and Disease, Philadelphia, Saunders, 1980, pp1482.
123.Fife D, Rappaport EB: Prevalence of salt losing among congenital adrenal hyperplasia patients. Clin Endocrinol 1983; 19:259-264.
124.Pang S, Hotchkiss J, Drash AL, et al: Microfilter paper method for 17α-progesterone radioimmunoassay:Its application for rapid screening for congenital adrenal hyperplasia, J Clin Endocrinol Metab 1977; 45:1003.
125. New MI:21-hydroxylase deficiency congenital adrenal hyperplasia. J Steroid Biochem Molec Biol. 1994; 48:15-22.
126. Owerbach D, Crawford YM, Draznin MB. Direct analysis of CYP21B genes in 21-hydroxylase deficiency using polymerase chain reaction amplification. Mol Endocrinol. 1990; 4:125-131.
127. Wilson RC, Wei J-Q, Cheng KC, et al:Rapid deoxyribonucleic acid analysis by allele-specific polymerase chain reaction for detection of mutations in the steroid 21-hydroxylase genes, J Clin Endocrinol Metab. 1995; 80:1635-1640.
128. New MI:Congenital adrenal hyperpalsia, in DeGroot LJ, Besser M, Burger HG, et al.(eds):Endocrinology, 3rd ed, Pennsylvania, W. S. Saunders Company. 1995, pp1813-1835.
129. Miller WL and Tyrrell JB:The adrenal Cortex, in Felig P, Baxter JD and Frohman LA(eds):Endocrinology and Metabolism, 3rd ed. New York, McGraw-Hill, Inc. 1995, pp555-711.